Development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system.
Quell Therapeutics has raised €138M across 1 funding round from 10 investors, most recently a Series B round in Nov 2021. Based in London, UK; active in Healthtech. Data as of 6 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-11-29 | Series B |
| €138M |
| British Patient Capital,Fidelity Management & Research Company LLC,Janus Henderson Investors,Jeito Capital,Monashee Investment Management LLC,Point72 Ventures+4 more |
| View deal → |
